fluticasone
Phase 3- Indications
- Eosinophilic esophagitis
Company intelligence / Profile preview
Ellodi Pharmaceuticals
Blue Bell, Pennsylvania, United Statesellodipharma.com ↗
- Ownership
- Private
- Development stage
- Phase 3
01
Overview
Ellodi Pharmaceuticals' lead asset, APT‑1011, an orally disintegrating tablet of fluticasone propionate, has shown encouraging results in Phase 3 clinical trials for Eosinophilic Esophagitis. The FLUTE‑2 study demonstrated greater complete symptomatic response rates and improved fibrostenotic features compared to placebo. The company received FDA Fast Track designation for APT‑1011 based on positive Phase 2b data[4][5][7].
- Therapeutic areas
- Gastroenterology
- Modalities
- Small molecules (glucocorticoids)
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Ellodi Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ellodi Pharmaceuticals.